A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Study Summary

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.

Conditions

Prostatic Neoplasms

Interventions / Drugs

Radiotherapy LHRHa Apalutamide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment693 participants

Primary Completion—

Lead SponsorJanssen Pharmaceutica N.V., Belgium

Data Retrieved2026-04-11 02:55:31.550346+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.